title: Lytic therapy in central venous catheters for hemodialysis.
abstract: Over the past 2 decades the use of central venous catheters (CVCs) for hemodialysis has become commonplace. While these devices have provided much needed temporary access to the bloodstream, they often become thrombosed and require procedures to restore patency. This article examines the lytic enzymes that are currently available and focuses on the assessment and treatment of thrombosis.
authors.affiliation: Nephrology Department, UNC School of Medicine in Chapel Hill, NC, USA.
authors.forename: Holly Fadness
authors.initials: HF
authors.lastname: McFarland
authors.forename: Lesley
authors.initials: L
authors.lastname: Dinwiddie
authors.forename: Janice
authors.initials: J
authors.lastname: Ferrell
authors.forename: Sue
authors.initials: S
authors.lastname: Forloines-Lynn
mesh_terms: D002405:Catheterization, Central Venous / Q000009:adverse effects* / Q000451:nursing; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage; D006435:Renal Dialysis / Q000009:adverse effects*; D013300:Streptokinase / Q000008:administration & dosage; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; C087896:reteplase; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator